Skip to main content
Premium Trial:

Request an Annual Quote

Aurora Biosciences Gets $75 M Private Placement



AN DIEGO--Aurora Biosciences has agreed to sell 1.8 million shares of newly issued common stock to selected institutional and other accredited investors for $75 million. The purchase price is $42 per share. The company intends to use net proceeds from this private placement for development and acquisition of new technologies, particularly in genomics and drug discovery, as well as commercial development and for working capital and other general corporate purposes.

Filed under

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.